| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
57,080,000 |
| Market
Cap: |
196.93(M) |
| Last
Volume: |
97,895 |
Avg
Vol: |
97,622 |
| 52
Week Range: |
$1.32 - $4.2 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.5 |
| Insider 6 Months : 5.2 |
| Insider 3/6 Months : 9.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,500 |
4,000 |
5,598 |
32,898 |
| Total Buy Value |
$10,840 |
$11,733 |
$14,587 |
$57,671 |
| Total People Bought |
2 |
3 |
3 |
5 |
| Total Buy Transactions |
2 |
3 |
4 |
11 |
| Total Shares Sold |
25,000 |
25,000 |
25,000 |
45,000 |
| Total Sell Value |
$76,500 |
$76,500 |
$76,500 |
$118,240 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
2 |
2 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lewis Joel |
Director |
– • – |
2019-01-29 |
4 |
B |
$4.81 |
$4,805 |
D/D |
1,000 |
64,133 |
2.31 |
- |
|
| Uihlein Richard E |
Director |
– • • |
2019-01-29 |
4 |
B |
$4.87 |
$236,244 |
D/D |
48,500 |
2,586,789 |
3.92 |
- |
|
| Uihlein Richard E |
Director |
– • • |
2019-01-28 |
4 |
B |
$4.77 |
$14,315 |
D/D |
3,000 |
2,538,289 |
3.92 |
- |
|
| Amelio Gilbert F |
Director |
– • – |
2019-01-21 |
4 |
D |
$4.75 |
$185,716 |
D/D |
(39,098) |
184,614 |
|
- |
|
| Amelio Gilbert F |
Director |
– • – |
2019-01-21 |
4 |
OE |
$0.89 |
$185,713 |
D/D |
103,750 |
215,935 |
|
- |
|
| Uihlein Richard E |
Director |
– • • |
2019-01-16 |
4 |
A |
$4.72 |
$34,999 |
D/D |
7,415 |
2,535,289 |
|
- |
|
| Lewis Joel |
Director |
– • – |
2019-01-16 |
4 |
A |
$4.72 |
$55,002 |
D/D |
11,653 |
63,133 |
|
- |
|
| Czirr James C |
Managing Member of GP |
– – – |
2019-01-11 |
4 |
OE |
$1.12 |
$8,508,089 |
D/D |
3,789,346 |
6,509,301 |
|
- |
|
| Eldred Kary |
Director |
– • – |
2018-09-25 |
4 |
B |
$6.10 |
$12,200 |
D/D |
2,000 |
41,382 |
2.39 |
- |
|
| Omenn Gilbert S |
Director |
– • – |
2018-09-10 |
4 |
S |
$6.00 |
$50,220 |
D/D |
(8,370) |
48,191 |
|
- |
|
| Omenn Gilbert S |
Director |
– • – |
2018-09-07 |
4 |
S |
$6.03 |
$66,365 |
D/D |
(11,000) |
56,561 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2018-09-04 |
4 |
AS |
$6.58 |
$78,256 |
D/D |
(11,900) |
20,581 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2018-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
32,481 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2018-08-30 |
4 |
AS |
$6.08 |
$353,312 |
D/D |
(58,100) |
26,481 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2018-08-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,000 |
84,581 |
|
- |
|
| Lewis Joel |
Director |
– • – |
2018-06-25 |
4 |
B |
$7.06 |
$7,058 |
D/D |
1,000 |
51,480 |
2.39 |
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2018-06-20 |
4 |
S |
$8.08 |
$786,034 |
D/D |
(97,267) |
1,260 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2018-06-20 |
4 |
OE |
$4.41 |
$428,947 |
D/D |
97,267 |
98,527 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2018-06-19 |
4 |
S |
$9.01 |
$1,159,987 |
D/D |
(128,733) |
1,260 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2018-06-19 |
4 |
OE |
$3.45 |
$542,753 |
D/D |
128,733 |
129,993 |
|
- |
|
| 10x Capital Management, Llc |
10% Owner |
– – • |
2018-06-18 |
4 |
AS |
$9.06 |
$543,600 |
I/I |
(60,000) |
2,649,786 |
|
- |
|
| Czirr James C |
Director |
– • – |
2018-06-18 |
4 |
AS |
$9.06 |
$543,600 |
I/I |
(60,000) |
2,649,786 |
|
- |
|
| 10x Capital Management, Llc |
10% Owner |
– – • |
2018-06-15 |
4 |
AS |
$8.47 |
$131,073 |
I/I |
(15,475) |
2,709,786 |
|
- |
|
| Czirr James C |
Director |
– • – |
2018-06-15 |
4 |
AS |
$8.47 |
$131,073 |
I/I |
(15,475) |
2,709,786 |
|
- |
|
| 10x Capital Management, Llc |
10% Owner |
– – • |
2018-06-14 |
4 |
AS |
$7.99 |
$632,133 |
I/I |
(76,385) |
2,725,261 |
|
- |
|
516 Records found
|
|
Page 8 of 21 |
|
|
0.05 (1.43%) 
